In 1957, Hillestad et al. defined acute promyelocytic leukemia (APL) for the first time in the
literature as a distinct type of acute myeloid leukemia (AML) with a “rapid downhill course” …

In the past few years research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …

Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia
(AML) that is used for prognostic, predictive, monitoring, and efficacy-response …

The combination of all-trans-retinoic acid (ATRA) plus arsenic trioxide (ATO) has been
shown to be superior to ATRA plus chemotherapy in the treatment of standard-risk patients …

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia.
Morphologically, it is identified as the M3 subtype of acute myeloid leukemia by the French …

Historically, acute promyelocytic leukemia (APL) was considered to be one of the most fatal
forms of acute leukemia with poor outcomes before the introduction of the vitamin A …

The introduction of all-trans retinoic acid (ATRA) and, more recently, arsenic trioxide (ATO)
into the therapy of acute promyelocytic leukemia (APL) has revolutionized the management …

Cancer remains a major killer of mankind. Failure of conventional chemotherapy has
resulted in recurrence and development of virulent multi drug resistant (MDR) phenotypes …

Purpose We investigated the effect on outcome of measurable or minimal residual disease
(MRD) status after each induction course to evaluate the extent of its predictive value for …

Although improvement in outcomes has occurred in younger adults with acute myeloid
leukemia (AML) during the past 4 decades, progress in older adults has been much less …